The UK research landscape today
Diabetes research in Britain runs on two parallel tracks. Large industry-sponsored studies, tracked through registries like ClinicalTrials.gov and ISRCTN, test new medicines and devices in real NHS settings. Alongside them sit university-led projects, often funded through programmes like the Type 1 Diabetes Grand Challenge, which look further ahead at prevention and even potential cures.
What stands out about the current wave is how close it sits to everyday care. Researchers are no longer only chasing exotic molecules in lab settings. They are asking practical questions: can a weekly injection replace daily insulin, can continuous glucose monitors work in ordinary GP surgeries, and can AI spot complications before they appear.
For people living with diabetes, this means more entry points into research than ever before. Trials are recruiting in cities from Birmingham to Newcastle, and NHS trusts in places like Bradford and Exeter are running studies that blend new technology with familiar routines.
What is in the pipeline
Several studies illustrate where diabetes management is heading.
Weekly insulin. NICE has backed insulin efsitora alfa, sold as Onswik, after clinical trials showed it controls blood glucose as effectively as daily insulin. Around a quarter of the more than four million type 2 diabetics in Britain need injections, and a weekly option could relieve the burden of daily routines for those who struggle with adherence.
A new type 2 diabetes treatment. Eli Lilly is running a Phase 2 study of LY3457263, comparing it with placebo in people already on a stable dose of semaglutide or tirzepatide. UK sites include Birmingham, Blackpool, Bristol, Bromborough and Newcastle.
Preserving the pancreas in type 1 diabetes. Teplizumab, already approved in the United States, is being tested through the NHS in early-stage type 1 diabetes. It trains the immune system to stop attacking insulin-producing cells, delaying the need for insulin by around three years on average. A 36-year-old dentist from Devon, Hannah Robinson, became the first adult in Britain to receive it at the Royal Devon University Healthcare NHS Foundation Trust.
Weight and blood sugar together. Bradford Teaching Hospitals NHS Foundation Trust has opened two investigational trials of a weekly injection aimed at people living with obesity, with or without type 2 diabetes. Participants must be over 18, be living with obesity or overweight, and have at least one weight-related condition such as high blood pressure, abnormal cholesterol, obstructive sleep apnoea or cardiovascular disease.
Continuous glucose monitoring in primary care. The Dexcom ONE+ system, already approved and CE marked in the UK, is being studied in a primary care setting. The trial (ISRCTN12336055) looks at whether CGM improves blood sugar control and fits into routine care without disrupting practice. Adults with type 2 diabetes on insulin for at least three months can take part.
AI-driven prevention. Researchers at the University of Exeter trained an AI tool using data from one million people in the UK. It uses simple characteristics like sex and weight to match individuals to the most effective drug combinations, and AI is now also used in diabetic eye screening to speed up analysis of thousands of images.
A comparison of current trial approaches
| Trial or approach | What it targets | How it is delivered | Who it suits best | Main advantage | What to weigh up |
|---|
| Weekly insulin (Onswik) | Type 2 diabetes needing injections | One injection per week via NHS | People who find daily injections hard to maintain | Simpler routine, similar glucose control | Change from familiar daily schedule |
| Eli Lilly Phase 2 study | Type 2 diabetes on GLP-1 treatment | Investigational medicine vs placebo, study clinics | Those stable on semaglutide or tirzepatide | Access to an emerging treatment | Requires time for study visits |
| Teplizumab | Early-stage type 1 diabetes | Infusion, research setting only | Newly diagnosed adults and children | May delay insulin need for years | Only available through research currently |
| Bradford obesity trials | Obesity with or without type 2 diabetes | Weekly injection, NHS research site | Adults 18+ with weight-related conditions | Addresses weight and glucose together | Eligibility criteria are specific |
| Dexcom ONE+ primary care study | Type 2 diabetes on insulin | CGM worn continuously | Adults in primary care | Better glucose insight day to day | Requires wearing a sensor |
| AI risk tools (Exeter) | Type 2 diabetes detection and drug matching | Analysis based on routine data | Whole populations, early risk | Catches complications sooner | Still in development phases |
Making sense of participation
Joining a trial is a personal decision, and the honest picture includes trade-offs. Study visits take time, treatment may be a placebo, and you should keep managing your diabetes as your usual care team advises throughout.
That said, participants consistently describe benefits beyond the medicine itself. Regular monitoring, closer contact with specialists, and access to devices or therapies not yet widely available are common experiences. For many, there is also a quiet sense of contribution, knowing the results will shape care for the people diagnosed after them.
How to find and join a trial near you
- Start with your diabetes team. Mention your interest at your next review. Clinicians often know which studies are recruiting locally before public listings are updated.
- Check the registries. Search ClinicalTrials.gov or ISRCTN for studies with UK sites. Filter by condition, phase and city, then contact the study team directly.
- Look at NHS trust research pages. Trusts like Bradford Teaching Hospitals, Royal Devon University Healthcare, and University Hospitals Birmingham publish their recruiting studies online.
- Contact Diabetes UK. The charity runs a research involvement network and can point you toward suitable opportunities.
- Ask the eligibility questions. Age, current medication, and conditions like high blood pressure or sleep apnoea all matter. Each study team will confirm whether you fit.
The UK runs one of the most active diabetes research environments in Europe, with more than 140 cities hosting sites for industry-sponsored studies alone. Whether your goal is simpler daily routines, better glucose insight, or contributing to science, there is likely a trial that matches your situation.
Talking through options with your GP or consultant is the safest first step. If a study seems like a fit, the team will walk you through what is involved before you commit. Diabetes management is evolving faster than ever, and British patients are in a strong position to benefit from that progress.
研究の知恵